Background and purpose: An increasing number of studies have revealed that microRNAs (miRNAs) are the main drivers of hepatocarcinogenesis including progression to later stages of liver cancer. Recently, miR-548b was identified as a cancer-related miRNA in glioma and tongue squamous cell carcinoma. Nonetheless, the expression pattern and specific roles of miR-548b in hepatocellular carcinoma (HCC) have not yet been clarified. Methods: Expression levels of miR-548b in HCC tissues and cell lines were measured by reverse-transcription quantitative PCR. In vitro and in vivo functional assays were performed to determine the effects of miR-548b on the malignant phenotypes of HCC cells. In addition, the molecular mechanisms by which miR-548b regulates the initiation and progression of HCC were investigated in detail. Results: miR-548b expression was weak in HCC tissues and cell lines. The low miR-548b expression significantly correlated with tumor size, TNM stage, and venous infiltration of HCC. In addition, exogenous miR-548b expression suppressed HCC cell proliferation, colony formation, and metastasis and induced apoptosis in vitro. Silencing of miR-548b exerted an opposite effect on these characteristics of HCC cells. Furthermore, miR-548b overexpression hindered tumor growth in vivo. Mechanistic analysis identified high-mobility group box 1 (HMGB1) as a direct target gene of miR-548b in HCC cells. Moreover, an HMGB1 knockdown reproduced the effects of miR-548b upregulation on HCC cells. Recovered HMGB1 expression reversed the effects of miR-548b on HCC cells. Notably, miR-548b overexpression deactivated the PI3K-AKT pathway in HCC cells in vitro and in vivo. Conclusion: Our findings provide the first evidence that miR-548b restrains HCC progression, at least partially, by downregulating HMGB1 and deactivating the PI3K-AKT pathway. Thus, miR-548b might be a novel target for the development of new therapies for HCC.
Introduction
Hepatocellular carcinoma (HCC), the most prevalent primary liver cancer, is the fifth most common malignant tumor and the third main cause of cancer-related deaths worldwide. 1 Currently, multiple therapeutic approaches, including surgical improved; 3 unfortunately, HCC remains a deadly cancer, with a 5-year survival rate of less than 5%. 4 Postoperative recurrence and high frequency of intrahepatic and extrahepatic metastases are the primary causes of the poor prognosis of patients with HCC. 5 The pathogenesis of HCC is complicated, and various risk factors, such as infection with hepatitis virus B or C, exposure to aflatoxin B1, and genetic and epigenetic alterations, play crucial roles in HCC tumorigenesis; 6, 7 however, the detailed molecular mechanisms are still largely unclear; this situation is another important reason for the unsatisfactory therapeutic outcomes. Therefore, further exploration of the exact mechanisms is urgently necessary and will help to identify effective targets for antineoplastic therapy. MicroRNAs (miRNAs) are a family of small endogenous noncoding RNA molecules of~17-23 nucleotides. 8 MiRNAs are widely expressed in animals, plants, and even viruses and perform crucial functions in almost all physiological and pathological processes. 9 MiRNAs negatively regulate gene expression by binding to the 3′ untranslated region (UTR), thus triggering either messenger RNA (mRNA) degradation or translational suppression. 10 Increasing numbers of reports have revealed that many miRNAs are aberrantly expressed in HCC and have indicated the involvement of miRNAs in hepatocarcinogenesis including progression to later stages of liver cancer. [11] [12] [13] A growing body of experimental evidence suggests that miRNAs can exert oncogenic or tumor-suppressive actions in HCC and can regulate a wide range of biological phenomena, such as cell proliferation, apoptosis, cell cycle, metastasis, epithelial-mesenchymal transition, and chemoresistance. [14] [15] [16] Thus, miRNAs may be promising targets for noninvasive treatment of HCC. Recently, miR-548b was recognized as a cancer-related miRNA in glioma 17 and tongue squamous cell carcinoma. 18 Nevertheless, the expression pattern and specific involvement of miR-548b in HCC have not yet been clarified. In this study, we aimed to assess the miR-548b expression and to investigate its functions in HCC. In addition, the molecular mechanisms by which miR-548b regulate the progression of HCC were explored in detail.
Materials and methods

Clinical samples
HCC and normal paracarcinoma tissue samples were collected from 59 patients who were newly diagnosed as having HCC and were treated with surgical resection at The First Hospital of Jilin University between August 2015 and October 2017. None of these patients had received preoperative percutaneous ablation, radiotherapy, chemotherapy, or other anticancer therapy. Prior to experiments, all tissues were frozen in liquid nitrogen and stored at −80°C. The study protocol was approved by the Ethics Committee of The First Hospital of Jilin University and was in compliance with the guidelines of the Declaration of Helsinki. In addition, written informed consent was obtained from all the participants or their relatives.
Cell culture
Four HCC cell lines (Hep3B, Huh7, SK-HEP-1, and Bel-7402) and an immortalized normal human liver epithelial cell line (L02) were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All the cell lines were maintained at 37°C in a humidified atmosphere containing 5% of CO 2 and were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% of the fetal bovine serum (FBS; Gibco, Thermo Fisher Scientific, Inc.), 100 μg/mL streptomycin, and 100 U/mL penicillin (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany).
A transfection assay
MiR-548b mimics, an miR-548b inhibitor, negative control mimics (NC mimics), and a negative control inhibitor (NC inhibitor) were purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China), whereas synthetic small interfering RNA (siRNA) against HMGB1 expression (si-HMGB1) and negative control siRNA (si-NC) from Shanghai GenePharma Co., Ltd. (Shanghai, China). HMGB1 plasmid pCMV-HMGB1 and empty plasmid pCMV were synthesized by OriGene (Rockville, MD, USA). Cells were seeded in six-well plates at a density of 4 × 10 5 cells per well and grown to 70-80% confluence. A cell transfection assay was performed with Lipofectamine™ 2000 (Invitrogen, Thermo Fisher Scientific, Inc.). All the procedures of the transfection assay were based on the product specifications. After transfection for 6 hrs, the cells were washed with phosphatebuffered saline (PBS; Gibco, Thermo Fisher Scientific, Inc.) and cultured in fresh DMEM containing 10% of FBS.
RNA isolation and reverse-transcription quantitative PCR (RT-qPCR)
The miRcute Extraction and Separation of miRNAs Kit (DP501; Tiangen, Beijing, China) was used to extract miRNAs from cells and homogenized tissues. For evaluation of the miR-548b expression, cDNA synthesis was carried out with the miScript Reverse Transcription Kit (Qiagen GmbH, Hilden, Germany). After that, qPCR was performed on an Applied Biosystems 7500 Fast Real-Time PCR System (Thermo Fisher Scientific, Inc.) with the miScript SYBR Green PCR Kit (Qiagen GmbH). U6 small nuclear RNA served as an internal reference for the normalization of miR-548b expression.
To quantify HMGB1 mRNA expression, total RNA was isolated by means of the TRIzol reagent (Invitrogen, Thermo Fisher Scientific, Inc.). cDNA was synthesized from total RNA by reverse transcription using the PrimeScript™ RT reagent kit (TaKaRa, Dalian, China). Next, SYBR® Premix Ex Taq™ (TaKaRa) was employed to carry out qPCR. GAPDH mRNA served as the endogenous control for HMGB1 mRNA expression. Relative gene expression was calculated by the 2 −ΔΔCq method.
-H-tetrazolium bromide (MTT) assay
Transfected cells were seeded in 96-well plates at initial density 2× 10 3 cells/well and were cultured at 37°C and 5% CO 2 . After cultivation for 0, 1, 2, or 3 days, 20 µL of the MTT solution (5 mg/mL; Sigma-Aldrich, Merck KGaA) was added into each well and incubated with the cells for additional 4 h at 37°C and 5% CO 2 . Next, the culture medium was gently removed, and 200 µL of dimethyl sulfoxide (Beyotime Institute of Biotechnology, Inc., Shanghai, China) was added into each well to dissolve the formazan crystals. Finally, absorbance was read at 490 nm on a microplate reader (Bio-Rad, Hercules, CA, USA).
A clonogenic assay
This assay was conducted to determine the colony formation capacity of cells. Transfected cells were seeded in six-well plates at a density of 1,000 cells per well. The cells were allowed to grow at 37°C in a humidified atmosphere containing 5% of CO 2 for 2 weeks. The culture medium was refreshed every 3 days. On day 15, the colonies were washed with PBS, fixed with 75% methanol, and stained with 0.1% crystal violet. The number of colonies formed was photographed under an inverted light microscope and then counted (Nikon, Tokyo).
Flow-cytometric analysis
The apoptosis rate was determined using an Annexin V-Fluorescein Isothiocyanate (FITC) Apoptosis Detection Kit (BioLegend, San Diego, CA, USA . All the mice were euthanized at the final time point. The xenograft was removed and weighed.
Hematoxylin-eosin (HE) staining
Tumor xenografts were fixed in 4% paraformaldehyde solution, dehydrated, and embedded in paraffin. Four-micrometer frozen sections were prepared and subjected to staining using hematoxylin and eosin kit (Beyotime Institute of Biotechnology, Inc.). The staining was analyzed and observed using a light microscope (magnification, × 400).
Bioinformatic analysis
Two miRNA target prediction software packages, namely, TargetScan (http://www.targetscan.org/vert_71/) and microRNA (http://www.microrna.org/microrna/home.do), were used to search for putative targets of miR-548b.
A luciferase reporter assay
The fragments of the HMGB1 3′-UTR containing the wildtype or mutant miR-548b-binding site were amplified by Shanghai GenePharma Co., Ltd. The fragments were then cloned into the pmiR-RB-Report™ luciferase vector (Promega Corporation, Madison, WI, USA) to generate luciferase plasmids: pmiR-HMGB1-3ʹ-UTR wild-type and pmiR-HMGB1-3ʹ-UTR mut. Cells were seeded in 24-well plates and cotransfected with the wild-type or mutant luciferase plasmid and miR-548b mimics or the miR-548b inhibitor. The transfected cells were harvested 48 hrs after transfection, lysed, and assayed with a Dual-Luciferase reporter system (Promega Corporation, Madison, WI, USA). Renilla luciferase activity served for normalization.
Western blot analysis
Cells and tissues were lysed with radioimmunoprecipitation assay lysis buffer (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China). The concentration of total protein was quantified using the Bradford protein assay kit (Bio-Rad). Equal amounts of protein were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis in a 10% gel and were transferred to polyvinylidene fluoride membranes (Beyotime Institute of Biotechnology, Inc.). Next, the membranes were blocked with 5% skimmed milk (dry basis) and incubated with primary antibodies (1:1,000 dilution) overnight at 4°C. The primary antibodies were as follows: a mouse monoclonal anti-human HMGB1 (cat. # ab77302; Abcam, Cambridge, UK), rabbit monoclonal anti-human phospho-(p-)PI3k (ab182651; Abcam), mouse monoclonal anti-human p85 PI3k (ab189403; phospho Y607; Abcam), mouse monoclonal anti-human p-Akt (sc-271964; Santa Cruz Biotechnology, Dallas, TX, USA), mouse monoclonal anti-human Akt (sc-56878; Santa Cruz Biotechnology), and mouse monoclonal anti-human GAPDH (sc-166574; Santa Cruz Biotechnology). After extensive washing with Trisbuffered saline containing 0.05% of Tween 20 (TBST), the membranes were incubated with a secondary antibody: a horseradish peroxidase-conjugated goat anti-mouse IgG antibody (ab97046) or a goat anti-rabbit IgG antibody (ab97051; Abcam) at a 1:5,000 dilution. Finally, the membranes were washed thrice with TBST, and the protein signals were detected with an enhanced chemiluminescence detection kit (Sigma-Aldrich, Merck KGaA).
Statistical analysis
All the results are expressed as the mean ± standard deviation and were analyzed in SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). Differences between two groups were assessed by Student's t test, whereas oneway analysis of variance (ANOVA) followed by the Student-Newman-Keuls post hoc test was conducted to evaluate differences among multiple groups. The correlation between the expression of miR-548b and the clinical features of HCC patients was studied by the χ 2 test. The statistical significance of a positive correlation between miR-548b and HMGB1 mRNA was evaluated by Spearman's correlation analysis. Data with P<0.05 were considered statistically significant.
Results
miR-548b expression is frequently low in HCC tissues and cell lines
The expression level of miR-548b was analyzed in 59 pairs of HCC and normal paracarcinoma tissue samples by RTqPCR. Obviously, lower miR-548b expression in HCC tissue samples than in normal paracarcinoma tissues was observed ( Figure 1A , P<0.05). In addition, we analyzed miR-548b expression in four HCC cell lines: Hep3B, Huh7, SK-HEP-1, and Bel-7402. An immortalized normal human liver epithelial cell line (L02) served as a control. The data from RT-qPCR showed that miR-548b expression was lower in HCC tissue samples than in L02 cells ( Figure 1B , P<0.05). Thus, we concluded that miR-548b is frequently downregulated in HCC tumors and cell lines.
Clinical significance of underexpressed miR-548b in patients with HCC
To clarify the clinical meaning of miR-548b underexpression in HCC, we distributed the 59 HCC patients into two subgroups -miR-548b low-expression group (<median, n=30) and miR-548b high-expression group (≥median, n=29) -based on the median value of the miR-548b expression in HCC tissue samples. The results of the χ 2 test (Table 1) indicated that low miR-548b expression obviously correlated with tumor size (P=0.002), TNM stage (P=0.027), and venous infiltration of HCC (P=0.044). No significant association was observed between miR-548b expression and other clinical parameters, including patients' age (P=0.5247), gender (P=0.514), α-fetoprotein (AFP) levels (P=0.520), or the tumor number (P=0.417). These data suggested that miR548b underexpression may be related to HCC progression.
miR-548b inhibits proliferation and colony formation and induces apoptosis of HCC cells in vitro
HCC cell line Hep3B, which had the lowest miR-548b expression, was transfected with miR-548b mimics, whereas the miR-548b inhibitor was transfected into SK-HEP-1 cells, which manifested the highest miR-548b expression among the four HCC cell lines. Transfection efficiency was confirmed by RT-qPCR ( Figure 2A , P<0.05). MTT and clonogenic assays were performed to clearly determine the influence of miR-548b on HCC cell growth. The results revealed that artificial miR-548b upregulation decreased the proliferative and colony formation abilities of Hep3B cells; in contrast, the miR-548b knockdown enhanced the proliferative and colony formation abilities of SK-HEP-1 cells ( Figure 2B and C, P<0.05). Given that miR-548b significantly affected HCC cell proliferation, we next examined the role of miR-548b in the regulation of apoptosis by flow-cytometric analysis. The data showed that ectopic miR-548b expression induced apoptosis of Hep3B cells, whereas the knockdown of miR-548b had the opposite effect on SK-HEP-1 cells ( Figure 2D , P<0.05). These results indicate that miR-548b exerts a tumor-suppressive action in HCC cells in vitro.
miR-548b plays an inhibitory part in the metastasis of HCC cells
Transwell migration and invasion assays were carried out to test whether miR-548b restrains or promotes migration and invasiveness of HCC cells. The results indicated that restoration of miR-548b expression in Hep3B cells remarkably reduced their migratory and invasive abilities, whereas artificial downregulation of miR-548b in SK-HEP -1 cells significantly increased their migration and invasion ( Figure 3A and B, P<0.05). Thus, we preliminarily concluded that miR-548b might be a key suppressor of HCC metastasis.
HMGB1 mRNA is a target of miR-548b in HCC cells
To illustrate the potential molecular mechanisms by which miR-548b exerts its impact on the growth and metastasis of HCC cells, bioinformatic analysis was performed to predict a potential target of miR-548b. The 3′-UTR of HMGB1 mRNA contains a complementary site for miR-548b ( Figure 4A ), and this gene was chosen for validation because it has been implicated in hepatocarcinogenesis and cancer progression. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] To test whether miR-548b can directly target the 3′-UTR of HMGB1 mRNA, wild-type and mutant luciferase plasmids were chemically synthesized and cotransfected with miR-548b mimics or the miR-548b inhibitor into Hep3B and SK-HEP-1 cells. MiR-548b overexpression in Hep3B cells decreased, whereas the miR-548b knockdown in SK-HEP-1 cells increased the luciferase activity of the plasmid harboring a wild-type miR-548b-binding site (P<0.05). In contrast, alteration of miR-548b expression in Hep3B and SK-HEP-1 cells had no influence on the luciferase activity of the plasmid carrying the mutant binding site ( Figure 4B ). The expression levels of HMGB1 mRNA and protein in 59 pairs of HCC and normal paracarcinoma tissue samples were determined via RT-qPCR and Western blotting. The findings revealed that HMGB1 was highly expressed in HCC tissue samples at both mRNA ( Figure 4C , P<0.05) and protein levels ( Figure 4D , P<0.05) as compared with normal paracarcinoma tissue samples. In addition, the .2848, P<0.0001). Moreover, HMGB1 mRNA and protein expression in Hep3B cells were decreased by transfection with miR-548b mimics, whereas transfection with the miR-548b inhibitor raised HMGB1 mRNA and protein levels in SK-HEP-1 cells ( Figure 4G and H, P<0.05). Consequently, HMGB1 mRNA was demonstrated to be a target of miR-548b in HCC cells.
The HMGB1 knockdown and miR-548b upregulation exert similar effects in HCC cells
To elucidate the exact roles of HMGB1 in HCC tumorigenesis, an siRNA against HMGB1 (si-HMGB1) was utilized to knock down endogenous HMGB1 expression in Hep3B and SK-HEP-1 cells. Western blotting confirmed that HMGB1 expression was efficiently silenced in Hep3B and SK-HEP-1 cells that were transfected with si-HMGB1 ( Figure 5A , P<0.05). MTT and clonogenic assays were conducted to assess cell growth after the HMGB1 knockdown, and the results indicated that Hep3B and SK-HEP-1 cell proliferation ( Figure 5B , P<0.05) and colony formation ( Figure 5C , P<0.05) were notably suppressed in the si-HMGB1 group. Additionally, the percentage of apoptotic cells was obviously higher among the si-HMGB1-transfected Hep3B and SK-HEP-1 cells than among cells transfected with si-NC ( Figure 5D , P<0.05). Furthermore, the HMGB1 knockdown had an inhibitory influence on the metastasis ( Figure 5E and F, P<0.05) of Hep3B and SK-HEP-1 cells. These findings implied that HMGB1 silencing can mimic the tumor-suppressive activity of miR-548b overexpression in HCC cells, further supporting the idea that HMGB1 mRNA is a direct target of miR-548b.
Recovered HMGB1 expression reverses the effects of miR-548b in HCC cells
Rescue experiments were conducted to confirm that HMGB1 is involved in the anticancer activity of miR548b in HCC cells. MiR-548b-overexpressing Hep3B cells were transfected with HMGB1 plasmid pCMV-HMGB1, whereas si-HMGB1 was transfected into SK-HEP-1 cells after the miR-548b knockdown. Seventy-two hours after transfection, miR-548b mimic-mediated HMGB1 downregulation in Hep3B cells was reversed after cotransfection with pCMV-HMGB1. Besides, miR548b inhibitor-mediated upregulation of the HMGB1 protein in SK-HEP- 
miR-548b suppresses the PI3K-AKT pathway in HCC cells
HMGB1 has been reported to participate in the PI3K-AKT signaling pathway and thereby regulate carcinogenesis including cancer progression. 32, 33 Hence, we next determined whether miR-548b regulates the PI3K-AKT pathway in HCC cells through HMGB1. To test our hypothesis, we assayed the effects of miR-548b upregulation or knockdown on the cellular expression levels of PI3K-AKT pathwayrelated proteins. Firstly, we evaluated the transfection efficiency of pCMV-HMGB1 in Hep3B cells. As shown in Figure 7A , transfection of pCMV-HMGB1 notably increased the expression level of HMGB1 protein in Hep3B cells (P<0.05). The transfection efficiency of si-HMGB1 in SK-HEP-1 cells was already revealed in Figure 5A . Western blotting indicated that miR-548b overexpression decreased the protein levels of p-PI3K and p-AKT in Hep3B cells, whereas miR-548b downregulation increased the p-PI3K and p-AKT protein levels in SK-HEP-1 cells. Notably, normalization of HMGB1 expression reversed the changes in the p-PI3K and p-AKT amounts in Hep3B and SK-HEP-1 cells caused by the miR-548b upregulation or knockdown ( Figure 7B ). These data suggested that miR-548b inhibited the activation of the PI3K-AKT pathway in HCC cells. 
miR-548b inhibits tumor growth of HCC cells in vivo
Finally, a tumor xenograft model was set up to examine the impact of miR-548b on tumor growth in vivo. Hep3B cells transfected with miR-548b mimics or NC mimics were injected into nude mice. The tumor xenografts derived from miR-548b mimic transfectants obviously had smaller volume ( Figure 8A and B, P<0.05) and lesser weight ( Figure 8C , P<0.05) than did the tumor xenografts derived from the NC mimic transfectants. In addition, we measured miR-548b expression in the tumor xenografts by RT-qPCR. The tumor xenografts derived from miR-548b mimic-transfected Hep3B cells expressed more miR-548b relative to the cells transfected with the NC inhibitor ( Figure 8D , P<0.05). After that, HE staining was performed to reveal the tumor xenografts were real tumor tissues ( Figure 8E ). Western blot analysis was used to evaluate the protein expression in tumor xenografts. The protein amounts of HMGB1, p-PI3K, and p-AKT turned out to be obviously lower in the miR-548b mimics group ( Figure 8F ). These results meant that miR-548b overexpression inhibits HCC tumor growth in vivo by repressing HMGB1 expression and PI3K-AKT signaling.
Discussion
Dysregulation of miRNAs in HCC is reported frequently. [34] [35] [36] An increasing number of studies have proven that miRNAs are the main drivers of HCC tumorigenesis because they function as oncogenes or tumor suppressor genes. [37] [38] [39] Moreover, miRNA-based targeted therapies have been tested in several preclinical models, including HCC models. 40 Therefore, identification of oncogenic or tumor-suppressive miRNAs and detailed elucidation of their roles in HCC pathogenesis may help identify effective biomarkers for HCC diagnosis and prognosis as well as therapeutic targets in this cancer. MiR548b is underexpressed in glioma 17 and highly expressed in tongue squamous cell carcinoma. 18 Nonetheless, the expression status of miR-548b in HCC has been unclear. Hence, we measured the expression of miR-548b in HCC and found that miR-548b is downregulated in both HCC tissues and cell lines. Low miR-548b expression significantly correlated with tumor size, TNM stage, and venous infiltration of HCC. These findings suggest that miR-548b may serve as a biomarker for the diagnosis of HCC. MiR-548b has been identified as a tumor suppressor in glioma. Ectopic miR-548b expression inhibits the proliferation and metastasis of glioma cells in vitro and decreases tumor growth in vivo. 17 Mechanistic studies have revealed that metastasis tumor-associated protein 2 (MTA2) mRNA is a direct target of miR-548b in glioma cells, and MTA2 silencing is essential for the tumor-suppressive properties of miR-548b toward glioma. 17 On the other hand, the participation of miR-548b in HCC has rarely been reported. Herein, miR-548b upregulation dramatically decreased cell proliferation, colony formation, migration, and invasiveness of HCC cells and induced their apoptosis, whereas an miR548b knockdown exerted the opposite effects. Additionally, overexpression of miR-548b reduced HCC tumor growth in vivo. These observations suggest that miR-548b may be a therapeutic target in HCC.
In subsequent mechanistic experiments, bioinformatic analysis was first carried out to predict potential targets of miR-548b. The 3′-UTR of HMGB1 mRNA turned out to contain a highly conserved binding site for miR-548b. After that, a luciferase activity assay was performed to validate the targeting of miR-548b to the 3′-UTR of HMGB1 mRNA. Besides, HMGB1 expression was found to be high in HCC tissues and inversely correlated with miR-548b expression. By RT-qPCR and Western blotting, we detected a reduction in HMGB1 mRNA and protein levels in HCC cells after miR-548b overexpression, whereas the miR-548b knockdown had the opposite effect. Furthermore, silencing of HMGB1 reproduced the effects of miR-548b overexpression in HCC cells. Subsequent rescue experiments validated the notion that the expression changes of HMGB1 induced by miR-548b mediate the effects of miR-548b in HCC cells. Notably, miR-548b overexpression deactivated, whereas the miR-548b knockdown activated the PI3K-AKT pathway in HCC cells. Thus, to our knowledge, this study is the first to show that the miR-548b-HMGB1-PI3K-AKT pathway is implicated in the pathogenesis of HCC.
HMGB1 is a highly conserved DNA-binding protein that can relocate from the cytoplasm to nucleus and interact with transcription factors, nucleosomes, and histones. Multivariate analysis has identified high HMGB1 expression as an independent prognostic factor for the overall survival and disease-free survival of patients with HCC. 19, 20 Multiple pieces of evidence support the involvement of HMGB1 as an oncogene in HCC. HMGB1 performs crucial functions in the formation and progression of HCC by regulating a number of malignant properties, including rapid cell proliferation, immortality, suppressed apoptosis, an out-of-control cell cycle, angiogenesis, metastasis, epithelial-mesenchymal transition, and chemoresistance. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] In our current study, it was revealed that miR-548b directly targets HMGB1 mRNA and inhibits its protein expression, thereby inhibiting the aggressive characteristics of HCC cells. Our results, together with previous findings, suggest that silencing of HMGB1 via miR-548b restoration might be a promising therapeutic strategy against HCC.
Limitations
This study has several limitations. First, we did not examine the correlation between miR-548b and overall survival among patients with HCC. In addition, the effect of miR548b inhibition on tumor growth in vivo and in vivo was not tested in rescue experiments. Furthermore, tumor growth (ie, Ki67 or PCNA staining) and cell death (ie, annexin V staining) were not investigated in the grafted tumor tissues in mice. We aim to fill these gaps in our further research.
Conclusions
We demonstrated that miR-548b acts as a tumorsuppressive miRNA in HCC by inhibiting cell proliferation, colony formation, migration, and invasion in vitro, by promoting apoptosis in vitro, and by slowing in vivo tumor growth. Mechanistic assays confirmed HMGB1 mRNA as a direct target of miR-548b in HCC cells. Of note, miR548b deactivated the PI3K-AKT signaling cascade in HCC both in vitro and in vivo. Our identification of the miR-548b-HMGB1 axis can help researchers gain novel insights into the mechanisms underlying HCC initiation and progression and can facilitate the development of novel therapies for patients with this deadly disease.
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